Saxagliptin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
* Date of FDA Approval (Patent Expiration): 2009 (2021) | * Date of FDA Approval (Patent Expiration): 2009 (2021) | ||
* Projected Sales Peak: $1 Billion | * Projected Sales Peak: $1 Billion | ||
* Importance: It is the most recent drug treating [[Diabetes]] to be approved by the FDA. Effectiveness at nearly 20-fold lower doses compared to [[Sitagliptin]] & [[Vildagliptin], allowing for dramatically reduced [[Pharmacokinetics#Cmax|C<sub>max</sub>]] and [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] and a potentially improved side effect profile. Increasing evidence that all DPP-4 inhibitors can to certain malignant cancers.<ref>PMID:15735018</ref> | * Importance: It is the most recent drug treating [[Diabetes]] to be approved by the FDA. Effectiveness at nearly 20-fold lower doses compared to [[Sitagliptin]] & [[Vildagliptin]], allowing for dramatically reduced [[Pharmacokinetics#Cmax|C<sub>max</sub>]] and [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] and a potentially improved side effect profile. Increasing evidence that all DPP-4 inhibitors can to certain malignant cancers.<ref>PMID:15735018</ref> | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
